PURPOSE: There is a critical need for improvements in the noninvasive diagnosis of lung cancer. We hypothesized that matrix-assisted laser desorption ionization mass spectrometry (MALDI MS) analysis of the most abundant peptides in the serum may distinguish lung cancer cases from matched controls. PATIENTS AND METHODS: We used MALDI MS to analyze unfractionated serum from a total of 288 cases and matched controls split into training (n = 182) and test sets (n = 106). We used a training-testing paradigm with application of the model profile defined in a training set to a blinded test cohort. RESULTS: Reproducibility and lack of analytical bias was confirmed in quality-control studies. A serum proteomic signature of seven features in the training set reached an overall accuracy of 78%, a sensitivity of 67.4%, and a specificity of 88.9%. In the blinded test set, this signature reached an overall accuracy of 72.6 %, a sensitivity of 58%, and a specificity of 85.7%. The serum signature was associated with the diagnosis of lung cancer independently of gender, smoking status, smoking pack-years, and C-reactive protein levels. From this signature, we identified three discriminatory features as members of a cluster of truncated forms of serum amyloid A. CONCLUSIONS: We found a serum proteomic profile that discriminates lung cancer from matched controls. Proteomic analysis of unfractionated serum may have a role in the noninvasive diagnosis of lung cancer and will require methodological refinements and prospective validation to achieve clinical utility.
PURPOSE: There is a critical need for improvements in the noninvasive diagnosis of lung cancer. We hypothesized that matrix-assisted laser desorption ionization mass spectrometry (MALDI MS) analysis of the most abundant peptides in the serum may distinguish lung cancer cases from matched controls. PATIENTS AND METHODS: We used MALDI MS to analyze unfractionated serum from a total of 288 cases and matched controls split into training (n = 182) and test sets (n = 106). We used a training-testing paradigm with application of the model profile defined in a training set to a blinded test cohort. RESULTS: Reproducibility and lack of analytical bias was confirmed in quality-control studies. A serum proteomic signature of seven features in the training set reached an overall accuracy of 78%, a sensitivity of 67.4%, and a specificity of 88.9%. In the blinded test set, this signature reached an overall accuracy of 72.6 %, a sensitivity of 58%, and a specificity of 85.7%. The serum signature was associated with the diagnosis of lung cancer independently of gender, smoking status, smoking pack-years, and C-reactive protein levels. From this signature, we identified three discriminatory features as members of a cluster of truncated forms of serum amyloid A. CONCLUSIONS: We found a serum proteomic profile that discriminates lung cancer from matched controls. Proteomic analysis of unfractionated serum may have a role in the noninvasive diagnosis of lung cancer and will require methodological refinements and prospective validation to achieve clinical utility.
Authors: John Marshall; Peter Kupchak; Weimin Zhu; Jason Yantha; Tammy Vrees; Shirley Furesz; Kellie Jacks; Chris Smith; Inga Kireeva; Rulin Zhang; Miyoko Takahashi; Eric Stanton; George Jackowski Journal: J Proteome Res Date: 2003 Jul-Aug Impact factor: 4.466
Authors: Lance A Liotta; Mark Lowenthal; Arpita Mehta; Thomas P Conrads; Timothy D Veenstra; David A Fishman; Emanuel F Petricoin Journal: J Natl Cancer Inst Date: 2005-02-16 Impact factor: 13.506
Authors: Ahmedin Jemal; Taylor Murray; Elizabeth Ward; Alicia Samuels; Ram C Tiwari; Asma Ghafoor; Eric J Feuer; Michael J Thun Journal: CA Cancer J Clin Date: 2005 Jan-Feb Impact factor: 508.702
Authors: Brandon A Howard; Michael Z Wang; Michael J Campa; Christina Corro; Michael C Fitzgerald; Edward F Patz Journal: Proteomics Date: 2003-09 Impact factor: 3.984
Authors: Kiyoshi Yanagisawa; Yu Shyr; Baogang J Xu; Pierre P Massion; Paul H Larsen; Bill C White; John R Roberts; Mary Edgerton; Adriana Gonzalez; Sorena Nadaf; Jason H Moore; Richard M Caprioli; David P Carbone Journal: Lancet Date: 2003-08-09 Impact factor: 79.321
Authors: William L Bigbee; Vanathi Gopalakrishnan; Joel L Weissfeld; David O Wilson; Sanja Dacic; Anna E Lokshin; Jill M Siegfried Journal: J Thorac Oncol Date: 2012-04 Impact factor: 15.609
Authors: Chad V Pecot; Ming Li; Xueqiong J Zhang; Rama Rajanbabu; Ciara Calitri; Aaron Bungum; James R Jett; Joe B Putnam; Carol Callaway-Lane; Steve Deppen; Eric L Grogan; David P Carbone; John A Worrell; Karel G M Moons; Yu Shyr; Pierre P Massion Journal: Cancer Epidemiol Biomarkers Prev Date: 2012-02-28 Impact factor: 4.254
Authors: Christine H Chung; Erin H Seeley; Heinrich Roder; Julia Grigorieva; Maxim Tsypin; Joanna Roder; Barbara A Burtness; Athanassios Argiris; Arlene A Forastiere; Jill Gilbert; Barbara Murphy; Richard M Caprioli; David P Carbone; Ezra E W Cohen Journal: Cancer Epidemiol Biomarkers Prev Date: 2010-01-19 Impact factor: 4.254
Authors: Rachel M Ostroff; William L Bigbee; Wilbur Franklin; Larry Gold; Mike Mehan; York E Miller; Harvey I Pass; William N Rom; Jill M Siegfried; Alex Stewart; Jeffrey J Walker; Joel L Weissfeld; Stephen Williams; Dom Zichi; Edward N Brody Journal: PLoS One Date: 2010-12-07 Impact factor: 3.240